Literature DB >> 1417176

Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer.

J P Kim1, O J Kwon, S T Oh, H K Yang.   

Abstract

Results of 6589 gastric cancer operations at the Department of Surgery, Seoul National University Hospital, from 1970 to 1990 were reported. About two thirds (76.6%) were advanced gastric cancer (stages III and IV). The 5-year survival rate of operated stage III gastric cancer was only 30.6%, with frequent recurrence. Conversely, cell-mediated immunities of advanced gastric cancer patients were significantly decreased. Therefore, to improve the cure rate and to prevent or delay recurrence, curative surgery with confirmation of free resection margins and systematic lymph node dissection of perigastric vessels were performed and followed by early postoperative immunotherapy and chemotherapy (immunochemosurgery) in stage III patients. To evaluate the effect of immunochemosurgery, two randomized trials were studied in 1976 and 1981. In first trial, 5-fluorouracil, mitomycin C, and cytosine arabinoside for chemotherapy and OK 432 for immunotherapy were used. The 5-year survival rates for surgery alone (n = 64) and immunochemosurgery (n = 73) were 23.4% and 44.6%, respectively, a significant difference. In the second trial, there were three groups: group I, immunochemosurgery (n = 159); group II, surgery and chemotherapy (n = 77); and group III, surgery alone (n = 94). 5-Fluorouracil and mitomycin C for chemotherapy and OK-432 for immunotherapy were administered for 2 years. The 5-year survival rate of group I was 45.3%, significantly higher than the 29.8% of group II and than the 24.4% of group III. The postoperative 1-chloro-2.4-dinitrobenzene test, T-lymphocyte percentage, phytohemagglutinin- and con-A-stimulated lymphoblastogenesis and the antibody-dependent cell-mediated cytotoxicity test showed more favorable values in the immunochemosurgery group. Therefore, immunochemosurgery is the best multimodality treatment for advanced gastric cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1417176      PMCID: PMC1242606          DOI: 10.1097/00000658-199209000-00006

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  19 in total

1.  Treatment of gastric cancer, with special reference to the survivals of the cancer patients treated with multiple combination MFC therapy or immunochemotherapy of MFC plus OK-432 (NSC B116209).

Authors:  S Suga; H Tsunekawa; M Washino; N Makino; Z Tamura; S Goto
Journal:  Gastroenterol Jpn       Date:  1977

2.  Immunologic reactivity in patients with primary operable breast cancer.

Authors:  H J Wanebo; H T Thaler; J A Hansen; P P Rosen; G F Robbins; J A Urban; H F Oettgen; R A Good
Journal:  Cancer       Date:  1978-01       Impact factor: 6.860

Review 3.  Active immunotherapy.

Authors:  G Mathé
Journal:  Adv Cancer Res       Date:  1971       Impact factor: 6.242

4.  T N M classification for stomach cancer.

Authors:  B J Kennedy
Journal:  Cancer       Date:  1970-11       Impact factor: 6.860

5.  Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG.

Authors:  J U Gutterman; J O Cardenas; G R Blumenschein; G Hortobagyi; M A Burgess; R B Livingston; G M Mavligit; E J Freireich; J A Gottlieb; E M Hersh
Journal:  Br Med J       Date:  1976-11-20

Review 6.  Immunological factors which influence response to immunotherapy in malignant melanoma.

Authors:  D Morton; F R Eilber; R A Malmgren; W C Wood
Journal:  Surgery       Date:  1970-07       Impact factor: 3.982

7.  5-fluorouracil, adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer.

Authors:  J S MacDonald; P V Woolley; T Smythe; W Ueno; D Hoth; P S Schein
Journal:  Cancer       Date:  1979-07       Impact factor: 6.860

8.  BCG immunotherapy as a systemic adjunct to surgery in malignant melanoma.

Authors:  D L Morton; F R Eilber; E C Holmes; F C Sparks; K Ramming
Journal:  Med Clin North Am       Date:  1976-05       Impact factor: 5.456

9.  Carcinoma of the stomach. Why are we falling to improve survival?

Authors:  T E Weed; W Nuessle; A Ochsner
Journal:  Ann Surg       Date:  1981-04       Impact factor: 12.969

10.  Chemotherapy versus chemoimmunotherapy of head and neck cancer: report of a randomized study.

Authors:  S P Richman; R B Livingston; J U Gutterman; J Y Suen; E M Hersh
Journal:  Cancer Treat Rep       Date:  1976-05
View more
  22 in total

1.  Side-to-side jejunoileal anastomosis plus proximal loop ligation: a novel intestinal bypass model for diabetic rats.

Authors:  Jinyuan Duan; Lianwen Yuan; Jianping Zhou
Journal:  Obes Surg       Date:  2014-01       Impact factor: 4.129

2.  Time-varying pattern of recurrence risk for gastric cancer patients.

Authors:  Xing-Yu Feng; Ying-Bo Chen; Wei Wang; Yuan-Xiang Guan; Yuan-Fang Li; Shi Chen; Xiao-Wei Sun; Wei Li; Da-Zhi Xu; You-Qing Zhan; Xiao-Shi Zhang; Zhi-Wei Zhou
Journal:  Med Oncol       Date:  2013-02-24       Impact factor: 3.064

3.  Lung metastases in metastatic gastric cancer: pattern of lung metastases and clinical outcome.

Authors:  Jee Hyun Kong; Jeeyun Lee; Chin-A Yi; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Keon Woo Park; Won Ki Kang
Journal:  Gastric Cancer       Date:  2011-10-29       Impact factor: 7.370

4.  Significant prognostic factors by multivariate analysis of 3926 gastric cancer patients.

Authors:  J P Kim; Y W Kim; H K Yang; D Y Noh
Journal:  World J Surg       Date:  1994 Nov-Dec       Impact factor: 3.352

5.  Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials.

Authors:  Jian-Kun Hu; Zhi-Xin Chen; Zong-Guang Zhou; Bo Zhang; Jing Tian; Jia-Ping Chen; Li Wang; Chao-Hua Wang; Hong-Yan Chen; You-Ping Li
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

6.  Association of the GNAS1 T393C polymorphism with tumor stage and survival in gastric cancer.

Authors:  Hakan Alakus; Stefan P Mönig; Ute Warnecke-Eberz; Gül Alakus; Günther Winde; Uta Drebber; Klaus J Schmitz; Kurt W Schmid; Kathrin Riemann; Winfried Siffert; Elfriede Bollschweiler; Arnulf H Hölscher; Ralf Metzger
Journal:  World J Gastroenterol       Date:  2009-12-28       Impact factor: 5.742

7.  Rapid Improvement in Diabetes After Simple Side-to-side Jejunoileal Bypass Surgery: Does It Need a Ligation or Not?

Authors:  Quan Ren; Jinyuan Duan; Jiaqing Cao
Journal:  Obes Surg       Date:  2018-07       Impact factor: 4.129

8.  Radical surgery for gastric cancer in Singapore.

Authors:  T K Ti
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

9.  Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy.

Authors:  Chun-Nan Yeh; Shih-Ming Jung; Tsung-Wen Chen; Tsann-Long Hwang; Yi-Yin Jan; Miin-Fu Chen
Journal:  Langenbecks Arch Surg       Date:  2009-12-10       Impact factor: 3.445

Review 10.  Chemotherapy for patients with gastric cancer after complete resection: a network meta-analysis.

Authors:  Ya-Wu Zhang; Yu-Long Zhang; Hui Pan; Feng-Xian Wei; You-Cheng Zhang; Yuan Shao; Wei Han; Hai-Peng Liu; Zhe-Yuan Wang; Sun-Hu Yang
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.